Yarrow Bioscience, Inc.
YARWFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Yarrow Bioscience, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 11 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Oct 30, 2026. The latest institutional report shown is dated Jun 30, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| STALEY CAPITAL ADVISERS INC | 2026-06-30 | 51,472 | Not shown | SEC filing |
| STALEY CAPITAL ADVISERS INC | 2026-03-31 | 51,472 | Not shown | SEC filing |
| Farther Finance Advisors, LLC | 2025-12-31 | 16 | Not shown | SEC filing |
| STALEY CAPITAL ADVISERS INC | 2025-12-31 | 51,472 | Not shown | SEC filing |
| STALEY CAPITAL ADVISERS INC | 2025-09-30 | 51,472 | Not shown | SEC filing |
| Farther Finance Advisors, LLC | 2025-09-30 | 16 | Not shown | SEC filing |
| Fortitude Family Office, LLC | 2025-09-30 | 680 | Not shown | SEC filing |
| Farther Finance Advisors, LLC | 2025-06-30 | 16 | Not shown | SEC filing |
| STALEY CAPITAL ADVISERS INC | 2025-06-30 | 51,472 | Not shown | SEC filing |
| STALEY CAPITAL ADVISERS INC | 2025-03-31 | 51,472 | Not shown | SEC filing |
| STALEY CAPITAL ADVISERS INC | 2024-12-31 | 36,472 | Not shown | SEC filing |
| STALEY CAPITAL ADVISERS INC | 2024-09-30 | 36,472 | Not shown | SEC filing |
| MB, LEVIS & ASSOCIATES, LLC | 2022-12-31 | 18,750 | Not shown | SEC filing |
| StoneX Group Inc. | 2022-12-31 | 13,837 | Not shown | SEC filing |
- Each value is checked against Yarrow Bioscience, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 14 rows: no share price from within three months of their report dates is on file, so they could not be checked.
- 4 rows left out: they repeat the same share count and value quarter after quarter, which a market value cannot do.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security. Filers with a row left out above, or with no row above to check, are not listed.
- STALEY CAPITAL ADVISERS INC: 51,472 shares reported 2026-03-31; 51,472 shares reported 2026-06-30.
- STALEY CAPITAL ADVISERS INC: 51,472 shares reported 2025-12-31; 51,472 shares reported 2026-03-31.
- STALEY CAPITAL ADVISERS INC: 51,472 shares reported 2025-09-30; 51,472 shares reported 2025-12-31.
- Farther Finance Advisors, LLC: 16 shares reported 2025-09-30; 16 shares reported 2025-12-31.
- STALEY CAPITAL ADVISERS INC: 51,472 shares reported 2025-06-30; 51,472 shares reported 2025-09-30.
- Farther Finance Advisors, LLC: 16 shares reported 2025-06-30; 16 shares reported 2025-09-30.
- STALEY CAPITAL ADVISERS INC: 51,472 shares reported 2025-03-31; 51,472 shares reported 2025-06-30.
- STALEY CAPITAL ADVISERS INC: 36,472 shares reported 2024-12-31; 51,472 shares reported 2025-03-31.
- STALEY CAPITAL ADVISERS INC: 36,472 shares reported 2024-09-30; 36,472 shares reported 2024-12-31.
3 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Yarrow Bioscience, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2021-01-28 · EDELMAN JOSEPH: Larger than all 12 other insider purchases of Common Stock on file. SEC filing
- 2020-06-09 · EDELMAN JOSEPH: Larger than 11 of the 12 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2023-03-20–2023-03-20: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2020-09-08–2020-09-08: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-01-15 | LEPORE PATRICK G · Director | Common Stock | P — Open market or private purchase | +15,000 | 2.92 | SEC filing |
| 2023-11-15 | LEPORE PATRICK G · Director | Common Stock | P — Open market or private purchase | +13,000 | 3.91 | SEC filing |
| 2023-03-20 | Harsch Mutya · Chief Legal Officer and GC | Common Stock | P — Open market or private purchase | +10,000 | 2.50 | SEC filing |
| 2023-03-20 | LEPORE PATRICK G · Director | Common Stock | P — Open market or private purchase | +20,000 | 2.48 | SEC filing |
| 2021-11-30 | LEPORE PATRICK G · Director | Common Stock | P — Open market or private purchase | +12,500 | 1.02 | SEC filing |
| 2021-08-25 | LEPORE PATRICK G · Director | Common Stock | P — Open market or private purchase | +12,500 | 1.60 | SEC filing |
| 2021-08-16 | EDELMAN JOSEPH · 10% owner | Common Stock | S — Open market or private sale | −250,000 | 1.74 | SEC filing |
| 2021-08-13 | EDELMAN JOSEPH · 10% owner | Common Stock | S — Open market or private sale | −250,000 | 1.84 | SEC filing |
Showing 8 of 14 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-10-29 | Payton Lori · Chief Development Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +99,827 | SEC filing |
| 2026-10-29 | Frey Rebecca · Chief Executive Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +465,857 | SEC filing |
| 2026-10-29 | Ryder Steven · Chief Medical Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +113,137 | SEC filing |
| 2026-10-29 | Zeronda Tyler · Chief Financial Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +156,115 | SEC filing |
| 2026-10-29 | Alford Rachael · Chief Operating Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +89,844 | SEC filing |
| 2026-07-27 | Ashiya Mona · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +15,435 | SEC filing |
| 2026-07-27 | Zeronda Tyler · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +185,798 | SEC filing |
| 2026-07-23 | Harsch Mutya · CHIEF LEGAL OFFICER AND GC | Common Stock | F — Payment of exercise price or tax by delivering securities | −22,516 | SEC filing |
Showing 8 of 22 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-07-29 | WONG RODERICK · 10% owner | Pre-Funded Warrants (Right to Buy) | J — Other acquisition or disposition | +133,290 | SEC filing |
| 2026-07-29 | WONG RODERICK · 10% owner | Common Stock | J — Other acquisition or disposition | −133,290 | SEC filing |
Showing 2 of 2 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.